Clinical Trial Update: Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/Phase 2 study evaluating the combination of atezolizumab and pirfenidone in second-line and beyond non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Esbriet (pirfenidone)
• Tecentriq (atezolizumab)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: NSCLC Stage IV, NSCLC, Recurrent | Phase 1, Phase 2 | Status: RECRUITING